Please use this identifier to cite or link to this item: http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5009
Full metadata record
DC FieldValueLanguage
dc.creatorGrégoire Wieërs-
dc.creatorNathalie Demotte-
dc.creatorDanièle Godelaine-
dc.creatorPierre Van der Bruggen-
dc.date2011-
dc.date.accessioned2013-05-30T12:06:45Z-
dc.date.available2013-05-30T12:06:45Z-
dc.date.issued2013-05-30-
dc.identifierhttp://www.mdpi.com/2072-6694/3/3/2904/-
dc.identifierhttp://www.doaj.org/doaj?func=openurl&genre=article&issn=20726694&date=2011&volume=3&issue=3&spage=2904-
dc.identifier.urihttp://koha.mediu.edu.my:8181/jspui/handle/123456789/5009-
dc.descriptionHuman tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International-
dc.sourceCancers-
dc.subjectanergy-
dc.subjectimmunosuppression-
dc.subjectcancer vaccines-
dc.subjectgalectin-
dc.subjecttumor-infiltrating lymphocytes-
dc.titleImmune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines-
Appears in Collections:Health Sciences

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.